World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: German Clinical Trials Register
Last refreshed on: 29 June 2014
Main ID:  DRKS00004592
Date of registration: 25/01/2013
Primary sponsor: Universitätsklinikum Freiburg Centrum für Chronische Immundefizienz (CCI)
Public title: Patients with mutations in the XIAP/BIRC4 gene
Scientific title: Patients with mutations in the XIAP/BIRC4 gene - XIAP
Date of first enrolment: 21/05/2012
Target sample size: 30
Recruitment status: Recruiting
URL:  http://www.drks.de/DRKS00004592
Study type:  observational
Study design:  Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Diagnostic;  
Countries of recruitment
Contacts
Key inclusion & exclusion criteria
Inclusion criteria: - patients with XLP-2 disease for whom a mutation in gene BIRC4/XIAP was diagnosed
- signed consent from the patient/parents for underaged patients

Exclusion criteria: - lack of signed consent from the patient/parents for underaged patients

Age minimum: no minimum age
Age maximum: no maximum age
Gender: Both, male and female
Health Condition(s) or Problem(s) studied
D80.0 - Hereditary hypogammaglobulinaemia
D82.3 - Immunodeficiency following hereditary defective response to Epstein-Barr virus
K50.9 - Crohn's disease, unspecified
Intervention(s)
Intervention 1: Patients with XLP, M. Crohn, EBV-infection, splenomegaly, hypogammaglobulinaemia and/or other symptoms for which a mutation in the gene BIRC4/XIAP was diagnosed. Enrolled patients will receive a venipuncture. Isolated patients cells are then flow cytometrically and genetically analyzed. Moreover, we establish cell lines to perform signalling pathway studies.
Primary Outcome(s)
Influence of different mutations in XIAP/BIRC4 on intracellular signalling
Secondary Outcome(s)
Not applicable
Secondary ID(s)
143/12
Source(s) of Monetary Support
Universitätsklinikum Freiburg Centrum für Chronische Immundefizienz (CCI)
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history